The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Wed, 03rd Feb 2021 11:49

Intuitive Investments Group PLC - closed-end investment company focused on life sciences sector - Acquires 2.2 million shares in Liverpool-based clinical stage drug development company Evgen Pharma PLC for 8 pence each, or GBP175,000 in total.

Acquisition was part of Evgen Pharma raising GBP10 million through an oversubscribed placing of 125 million shares at 8p each, the proceeds of which went towards "preclinical work for metastatic breast cancer, glioma and a further cancer indication yet to be announced" as well as as possible clinical trial in glioma patients.

This is Intuitive's fourth investment following its initial public offering in mid-December.

Current stock price: 25.00 pence

Year-to-date change: up 12%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Jun 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Feb 2020 16:17

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Read more
6 Feb 2020 13:45

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Read more
17 Dec 2019 15:35

Evgen Pharma narrows loss, foresees 'clinical success'

(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.

Read more
17 Dec 2019 11:28

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Read more
10 Dec 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Dec 2019 16:36

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Read more
5 Dec 2019 15:19

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Read more
11 Nov 2019 12:23

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

Read more
11 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

Read more
11 Nov 2019 09:11

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Read more
23 Sep 2019 13:09

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Read more
23 Sep 2019 10:03

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.

Read more
28 Aug 2019 14:30

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.

Read more
28 Aug 2019 12:06

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial that is testing its SFX-01 product, aimed at a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.